16th & 17th NovemberManchester, UK

 

Innovation Sponsor

Scientist.com profile

Online Market Place for R&D Outsourcing

Description: By enabling scientists to easily Outsource Everything but the GeniusĀ®, we are pioneering a faster, leaner and more innovation-centric approach to research. Our vision is to create a world in which scientists are limited only by their imagination.

Welcome

...to Biotech Outsourcing Strategies Manchester 2022

Launched in 2006 by Bio2Business Ltd, the Biotech Outsourcing Strategies Events bring together stakeholders in R&D outsourcing to share experience, build existing outsourcing partnerships and forge new buyer/supplier business relationships. The established BOS Formula is built on 4 key pillars; Exhibition showcasing international CROs and CMOs; High Quality Content (delivered through the multi-stream programme); 1-to-1 Partnering; Informal Networking (BOS Events are known for being friendly, intimate events, which create the perfect conditions for networking!).

We are delighted to bring the BOS Events to the north of England and to a city synonymous with industrial and technological progression. BOS Manchester 2022 will cover Discovery Outsourcing, Small Molecule CMC Outsourcing and Biologics CMC Outsourcing. We look forward to welcoming you to the events new home in the heart of Manchester.

Resources for Sponsors & Attendees


Our valued sponsors can access our Getting started with your BOS Manchester Sponsorship - Step-by-step Guide. In addition, sponsors can refer to a summary of the Exhibition Logistics. Book your accommodation at BOS Manchester 2022 by clicking here.

Covid restrictions were lifted in the United Kingdom in early 2022.

Follow us on LinkedIn to see our latest announcements


Featured Speaker (BOS Manchester 2022)

photo of Dr Jaclyn Raeburn

Parenteral Formulations: Tackling Development and Scalability Challenges of Ever-Increasing Formulation Complexity

Dr Jaclyn Raeburn, Manager, Formulation Development, Curia (formerly AMRI)

ABSTRACT: Parenteral injections allow a drug to be administered with up to 100 % bioavailability. Formulating a liquid drug product first and foremost must consider solubility and solution stability of the drug substance. Understanding these properties and limitations can see formulation development culminate in a simple aqueous formulation or develop into a more complex formulation such as an emulsion or dry-powder product. With increased sophistication of payload has emerged the use of liposomal and lipid nanoparticle technology which in itself provides stability challenges but also scalability challenges.... Click here to Read More


Featured Company (BOS Manchester 2022)

Logo for DIPHARMA FRANCIS
DIPHARMA FRANCIS
Dipharma Group is a global CDMO and a leading manufacturer of Active Pharmaceutical Ingredients and Intermediates. As part of the global pharmaceutical industry, we serve human health and, therefore, operate to the highest standards of quality and safety with proven experience in handling complex and...
View profile